No retraction, correction or concern found when last checked on Oct 20, 2026.

A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection

Danillo G. Augusto, Lawton D. Murdolo, Demetra S. M. Chatzileontiadou and 36 more

Nature · 2023 · CC BY

doi:10.1101/2021.05.13.21257065

Abstract

Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2 remain asymptomatic 1–4 . Although most global efforts have focused on severe illness in COVID-19, examining asymptomatic infection provides a unique opportunity to consider early immunological features that promote rapid viral clearance. Here, postulating that variation in the human leukocyte antigen ( HLA ) loci may underly processes mediating asymptomatic infection, we enrolled 29,947 individuals, for whom high-resolution HLA genotyping data were available, in a smartphone-based study designed to track COVID-19 symptoms and outcomes. Our discovery cohort ( n = 1,428) comprised unvaccinated individuals who reported a positive test result for SARS-CoV-2. We tested for association of five HLA loci with disease course and identified a strong association between HLA-B*15:01 and asymptomatic infection, observed in two independent cohorts. Suggesting that this genetic association is due to pre-existing T cell immunity, we show that T cells from pre-pandemic samples from individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF. The majority of the reactive T cells displayed a memory phenotype, were highly polyfunctional and were cross-reactive to a peptide derived from seasonal coronaviruses. The crystal structure of HLA-B*15:01–peptide complexes demonstrates that the peptides NQKLIANQF and NQKLIANAF (from OC43-CoV and HKU1-CoV) share a similar ability to be stabilized and presented by HLA-B*15:01. Finally, we show that the structural similarity of the peptides underpins T cell cross-reactivity of high-affinity public T cell receptors, providing the molecular basis for HLA-B*15:01 -mediated pre-existing immunity.

References 66

1.
Meyerowitz E. A., Richterman A., Bogoch I. I., Low N. & Cevik M. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect Dis 21, e163–e169 (2020 ).
Not in our library10.1016/s1473-3099(20)30837-9
2.
Oran D. P. & Topol E. J. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann Intern Med 173, M20–3012 (2020 ).
Not in our library10.7326/m20-3012
3.
Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis · 2020
No notice
4.
Ra S. H. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax 76, 61–63 (2021 ).
Not in our library10.1136/thoraxjnl-2020-215042
5.
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study · 2020
No notice
6.
Kwok A. J., Mentzer A. & Knight J. C. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet 22, 137–153 (2021 ).
Not in our library10.1038/s41576-020-00297-6
7.
The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic · 2020
No notice
8.
The Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New Engl J Med 383, 1522–1534 (2020 ).
Not in our library10.1056/nejmoa2020283
9.
Pairo-Castineira E. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021 ).
Not in our library10.1038/s41586-020-03065-y
10.
Gómez J., Albaiceta G. M., García-Clemente M., Garćıa-Gala J. M. & Coto E. DNA genotyping of the ABO gene showed a significant association of the A-group (A1/A2 variants) with severe COVID-19. Eur J Intern Med 88, 129–132 (2021 ).
Not in our library10.1016/j.ejim.2021.02.016
11.
Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? · 2006
No notice
12.
Sabeti P. C. Detecting recent positive selection in the human genome from haplotype structure. Nature 419, 832–837 (2002 ).
Not in our library10.1038/nature01140
13.
Walsh E. C. Searching for signals of evolutionary selection in 168 genes related to immune function. Hum Genet 119, 92–102 (2006 ).
Not in our library10.1007/s00439-005-0090-0
14.
Martin M. P. & Carrington M. Immunogenetics of HIV disease. Immunol Rev 254, 245–264 (2013 ).
Not in our library10.1111/imr.12071
15.
Blackwell J. M., Jamieson S. E. & Burgner D. HLA and infectious diseases. Clin Microbiol Rev 22, 370–85-- Table of Contents (2009 ).
Not in our library10.1128/cmr.00048-08
16.
Ng M. H. L. Immunogenetics in SARS: a case-control study. Hong Kong Medical J Xianggang Yi Xue Za Zhi Hong Kong Acad Medicine 16, 29–33 (2010 ).
Not in our library
17.
Association of HLA class I with severe acute respiratory syndrome coronavirus infection · 2003
Not checked
18.
Chen Y.-M. A. Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. J Clin Microbiol 44, 359–365 (2006 ).
Not in our library10.1128/jcm.44.2.359-365.2006
19.
Keicho N. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum Immunol 70, 527–531 (2009 ).
Not in our library10.1016/j.humimm.2009.05.006
20.
Wang S.-F. Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol 24, 421–426 (2011 ).
Not in our library10.1089/vim.2011.0024
21.
Ng M. H. L. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis 190, 515–518 (2004 ).
Not in our library10.1086/421523
22.
Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies · 2020
No notice
23.
Lee C. H. & Koohy H. In silico identification of vaccine targets for 2019-nCoV. F1000research 9, 145 (2020 ).
Not in our library10.12688/f1000research.22507.1
24.
Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2 · 2020
No notice
25.
Enayatkhani M. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study. J Biomol Struct Dyn 39, 1–19 (2020 ).
Not in our library10.1080/07391102.2020.1756411
26.
Augusto D. G. & Hollenbach J. A. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection. Curr Opin Immunol 76, 102178 (2022 ).
Not in our library10.1016/j.coi.2022.102178
27.
Mapping the human genetic architecture of COVID-19 · 2021
No notice
28.
Gragert L., Madbouly A., Freeman J. & Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol 74, 1313–1320 (2013 ).
Not in our library10.1016/j.humimm.2013.06.025
29.
The influence of HLA genotype on the severity of COVID‐19 infection · 2021
No notice
30.
Pappas D. J., Marin W., Hollenbach J. A. & Mack S. J. Bridging ImmunoGenomic Data Analysis Workflow Gaps (BIGDAWG): An integrated case-control analysis pipeline. Hum Immunol 77, 283–287 (2016 ).
Not in our library10.1016/j.humimm.2015.12.006
31.
Bland J. M. & Altman D. G. Multiple significance tests: the Bonferroni method. Bmj 310, 170 (1995 ).
Not in our library10.1136/bmj.310.6973.170
32.
Schwarzer G., Carpenter J. R. & Rücker G. Meta-Analysis with R. (Springer Cham). doi:.
Not in our library10.1007/978-3-319-21416-0
33.
Ma K.-Y. High-throughput and high-dimensional single-cell analysis of antigen-specific CD8+ T cells. Nat Immunol 22, 1590–1598 (2021 ).
Not in our library10.1038/s41590-021-01073-2
34.
J. J. S. Jr Multiple sclerosis therapies differentially impact SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. Jci Insight 7, e156978 (2022 ).
Not in our library10.1172/jci.insight.156978
35.
Chatzileontiadou D. S. M., Szeto C., Jayasinghe D. & Gras S. Protein purification and crystallization of HLA-A*02:01 in complex with SARS-CoV-2 peptides. Star Protoc 2, 100635 (2021 ).
Not in our library10.1016/j.xpro.2021.100635
36.
McPhillips T. M. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J Synchrotron Radiat 9, 401–406 (2002 ).
Not in our library10.1107/s0909049502015170
37.
XDS · 2010
No notice
38.
Phaser crystallographic software · 2007
No notice
39.
Project, N. 4 C. C. The CCP4 suite: programs for protein crystallography. Acta Crystallogr Sect D Biological Crystallogr 50, 760–763 (1994 ).
Not in our library10.1107/s0907444994003112
40.
Toor J. S. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations. Front Immunol 9, 99 (2018 ).
Not in our library10.3389/fimmu.2018.00099
41.
Features and development of Coot · 2010
No notice
42.
Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER · 2012
No notice
43.
Towards automated crystallographic structure refinement with phenix.refine · 2012
No notice
44.
Christophersen A. Peptide-MHC class I and class II tetramers: From flow to mass cytometry. Hla 95, 169–178 (2020 ).
Not in our library10.1111/tan.13789
45.
Davis M. M., Altman J. D. & Newell E. W. Interrogating the repertoire: broadening the scope of peptide–MHC multimer analysis. Nat Rev Immunol 11, 551–558 (2011 ).
Not in our library10.1038/nri3020
46.
Francis J. M. Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Sci Immunol eabk3070 (2021 ).
Not in our library10.1126/sciimmunol.abk3070
47.
Lineburg K. E. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses. Immunity 54, 1055–1065.e5 (2021 ).
Not in our library10.1016/j.immuni.2021.04.006
48.
SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 + T cell activation in COVID-19 patients · 2021
No notice
49.
Gangaev A. Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. Nat Commun 12, 2593 (2021 ).
Not in our library10.1038/s41467-021-22811-y
50.
Minervina A. A. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat Immunol 23, 781–790 (2022 ).
Not in our library10.1038/s41590-022-01184-4
51.
The pockets guide to HLA class I molecules · 2021
No notice
52.
Astbury S. HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology 166, 68–77 (2022 ).
Not in our library10.1111/imm.13450
53.
Schetelig J. Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity. Front Immunol 12, 698193 (2021 ).
Not in our library10.3389/fimmu.2021.698193
54.
Nguyen A., Yusufali T., Hollenbach J. A., Nellore A. & Thompson R. F. Minimal observed impact of HLA genotype on hospitalization and severity of SARS-CoV-2 infection. Hla 99, 607–613 (2022 ).
Not in our library10.1111/tan.14574
55.
Williams B. G., Gouws E., Boschi-Pinto C., Bryce J. & Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2, 25–32 (2002 ).
Not in our library10.1016/s1473-3099(01)00170-0
56.
Ge X., Guo Y., Cheng J., Hu R. & Feng X. Epidemiology and Seasonality of Respiratory Viruses Detected from Children with Respiratory Tract Infections in Wuxi, East China. Medical Sci Monit Int Medical J Exp Clin Res 24, 1856–1862 (2018 ).
Not in our library10.12659/msm.908483
57.
Childs A. The burden of respiratory infections among older adults in long-term care: a systematic review. Bmc Geriatr 19, 210 (2019 ).
Not in our library10.1186/s12877-019-1236-6
58.
Guthmiller J. J. & Wilson P. C. Remembering seasonal coronaviruses. Science 370, 1272–1273 (2020 ).
Not in our library10.1126/science.abf4860
59.
Seasonality of Respiratory Viral Infections: Will COVID-19 Follow Suit? · 2020
No notice
60.
An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease · 2021
No notice
61.
Bert N. L. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med 218, e20202617 (2021 ).
Not in our library10.1084/jem.20202617
62.
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 · 2020
No notice
63.
Kambayashi T., Assarsson E., Lukacher A. E., Ljunggren H.-G. & Jensen P. E. Memory CD8+ T Cells Provide an Early Source of IFN-γ. J Immunol 170, 2399–2408 (2003 ).
Not in our library10.4049/jimmunol.170.5.2399
64.
Ferretti A. P. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity 53, 1095–1107.e3 (2020 ).
Not in our library10.1016/j.immuni.2020.10.006
65.
Lipsitch M., Grad Y. H., Sette A. & Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat Rev Immunol 20, 709–713 (2020 ).
Not in our library10.1038/s41577-020-00460-4
66.
Aung S. Characteristics and Behaviors Associated with Prevalent SARS-CoV-2 Infection. Int J Gen Medicine 14, 1063–1067 (2021 ).
Not in our library10.2147/ijgm.s305990

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.